Eric Wasielewski

Lille, 59037, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Consistency of c-Met protein overexpression over time in patients with non-squamous non-small cell lung cancer.

Consistency of c-Met protein overexpression over time in patients with non-squamous non-small cell lung cancer.

Journal: Histopathology

Published: September 25, 2025

Pembrolizumab versus pembrolizumab plus chemotherapy in patients with PDL1 ⩾50% advanced non-small-cell lung cancer, depending on tumor aggressiveness and clinical impact.

Pembrolizumab versus pembrolizumab plus chemotherapy in patients with PDL1 ⩾50% advanced non-small-cell lung cancer, depending on tumor aggressiveness and clinical impact.

Journal: Therapeutic advances in medical oncology

Published: August 13, 2025

Impact of corticosteroids on the efficacy of first-line pembrolizumab plus chemotherapy in patients with advanced non-small-cell lung cancer.

Impact of corticosteroids on the efficacy of first-line pembrolizumab plus chemotherapy in patients with advanced non-small-cell lung cancer.

Journal: Therapeutic advances in medical oncology

Published: September 20, 2024

The impact of Charcot-Leyden Crystal protein on mesothelioma chemotherapy: targeting eosinophils for enhanced chemosensitivity.

The impact of Charcot-Leyden Crystal protein on mesothelioma chemotherapy: targeting eosinophils for enhanced chemosensitivity.

Journal: EBioMedicine

Published: February 09, 2024

Characterization of 164 patients with NRAS mutated non-small cell lung cancer (NSCLC).

Characterization of 164 patients with NRAS mutated non-small cell lung cancer (NSCLC).

Journal: Lung cancer (Amsterdam, Netherlands)

Published: July 16, 2023

Brief Report: Severe Sotorasib-Related Hepatotoxicity and Non-Liver Adverse Events Associated With Sequential Anti-Programmed Cell Death (Ligand)1 and Sotorasib Therapy in KRASG12C-Mutant Lung Cancer.

Brief Report: Severe Sotorasib-Related Hepatotoxicity and Non-Liver Adverse Events Associated With Sequential Anti-Programmed Cell Death (Ligand)1 and Sotorasib Therapy in KRASG12C-Mutant Lung Cancer.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: February 12, 2023

Excess of blood eosinophils prior to therapy correlates with worse prognosis in mesothelioma.

Excess of blood eosinophils prior to therapy correlates with worse prognosis in mesothelioma.

Journal: Frontiers in immunology

Published: January 20, 2023

HDAC Inhibition with Valproate Improves Direct Cytotoxicity of Monocytes against Mesothelioma Tumor Cells.

HDAC Inhibition with Valproate Improves Direct Cytotoxicity of Monocytes against Mesothelioma Tumor Cells.

Journal: Cancers

Published: March 15, 2022

Dual-Energy CT Perfusion of Invasive Tumor Front in Non-Small Cell Lung Cancers.

Dual-Energy CT Perfusion of Invasive Tumor Front in Non-Small Cell Lung Cancers.

Journal: Radiology

Published: November 16, 2021

Complete and prolonged response to anti-PD1 therapy in an ALK rearranged lung adenocarcinoma.

Complete and prolonged response to anti-PD1 therapy in an ALK rearranged lung adenocarcinoma.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: March 07, 2020

Redefining malignant pleural mesothelioma types as a continuum uncovers immune-vascular interactions.

Redefining malignant pleural mesothelioma types as a continuum uncovers immune-vascular interactions.

Journal: EBioMedicine

Published: July 14, 2019

Tumour assessment criteria for immune checkpoint inhibitors

Tumour assessment criteria for immune checkpoint inhibitors

Journal: Revue des maladies respiratoires

Published: June 19, 2017

Showing 1-12 of 13

Last Updated: 09/26/2026